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Abstract. Tenascin C (TNC) is a glycoprotein of the extracellular matrix and its 
overexpression induced by matrix metalloproteinases (MMPs) is associated with the 
amplification of the proliferative response to growth factors, promotion of cancer cell 
invasion and tumoral growth. This paper looks forward to find better inhibitors of MMPs, 
based on structure of batimastat (BAT) – a synthetic inhibitor of MMPs and an experimental 
drug against matrix metalloproteinase-16 (MMP16). To reach this aim, at first it was built a 
complete virtual library using 12 scaffolds (SCs) from BAT, concatenated via a dummy linker 
with 40 building blocks (BBs) found in 14 antineoplastic drugs. Second, all the derivatives 
from the virtual library were filtered, through mass-computation, for “drug-likeness”, 
undesirable moieties and checked if they are PAINS (Pan Assay Interference Compounds). At 
last, a virtual screening of “drug-like” virtual derivatives, free of undesirable moieties (except 
of the thiophene moiety) and BAT against the homologue model of MMP16 was made, using 
docking software in order to identify the compounds that specifically bind the enzyme. In the 
same time it was determinate the smallest binding energy required to bind MMP-16 to reveal 
the best ligands. Results show that 86 virtual derivates (1% of the 6720 derivates from the 
virtual library) are “drug-like” compounds. However, only 23 of the “drug-like” virtual 
derivates have better metrics than BAT, are free of undesirable moieties and are not PAINS.  
In addition, 15 of them are better ligands for MMP16 than BAT. 
 




TNC is a complex multifunctional protein, which has been shown to promote cell 
migration, inhibit focal contact formation, promote angiogenesis and, in some systems, act as 
a cell survival factor. Cell migration, a key factor for tumor invasion, metastasis and 
angiogenesis, is not possible without destruction of extracellular matrix (ECM) (Jones and 
Jones, 2000). ECM destruction is up regulated by proteolytic enzymes, particularly members 
of the matrix metalloproteinase (MMP) family. Overexpression of several MMPs has been 
described in many cancer types; several studies have indicated a role for TNC in regulating 
MMP gene expression (Tremble et al., 1994).  
Batimastat inhibits MMPs activity by binding the zinc ion from the active site of this 
class of metalloproteinases. BAT binds the MMPs with its thiophene moiety deeply inserted 
in the active site of this class of enzymes (Botos et al., 1996). In present, BAT is registered as 
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experimental drug against matrix metalloproteinase-16 (MMP16) in the public domain of 
DrugBank (http://www.drugbank.ca) with the accession number DB03880 (Knox et al., 2011; 
Wishart et al., 2006, 2008). The thiophene moiety, which gives BAT its specific binding 
ability to the active site of MMPs, is a flagged or intermediate substructure 
(substructure/compound that could be problematic in drug development process).  
Due to the enormous costs required be the development of new drugs, computational 
drug design became necessary owing its capability for handling large amounts of data and its 
multidimensional approach. Moreover, computer simulations are less costly per compound 
than any laboratory test, so the large compounds collections can be tested in silico with low 
expenses. The “drug-likeness” indicators, compulsory used for new drug development, do not 
indicate that a compound will be a good drug for a certain disease, but compounds that do not 
meet “drug-likeness” criteria frequently fail to be good drugs due to weak bioavailability, 
toxicity or ADME (administration, distribution, metabolism and excretion) problems (Young, 
2009). Binding properties play a major role over compound efficacy (the qualitative property 
of a compound having the desired effect) and its activity (the quantitative measure of how 
much of that compound is required to have a measured effect).  
The aim of this work, carried out entirely in silico, is to improve the “drug-likeness” 
metrics and to increase the binding properties of compounds from a full virtual library build 
on the backbone structure of BAT – due to its binding properties the thiophene moiety was 
conserved in the structure of all virtual derivates; even it is a flagged substructure. To avoid 
ADME and toxicity related issues of virtual derivates a very strict filtering for “drug-likeness” 
indicators was used. In addition, “drug-like” virtual derivates were checked for presence of 
undesirable moieties and if they can be PAINS. Finally, “drug-like” virtual derivates free of 
undesirable moieties (except of thiophene moiety, present in the backbone structure of all 
compounds from virtual library), classified as “intermediate compounds”, and together with 
BAT were submitted for virtual screening against the homologue model of MMP16.  
 
MATERIALS AND METHODS 
 
Entire work was made computationally. MarvinSketch was used for drawing of the 
chemical structures, generation of SMILES (Simplified Molecular Input Line Entry System) 
strings for SCs and BBs, tridimensional (3D) optimization of chemical structures for BAT and 
“intermediate compounds” and displaying of the chemical structures, MarvinSketch 5.5.0.1, 
2011, ChemAxon (http://www.chemaxon.com). MarvinView was used for displaying of all 
compound libraries and export as stand-alone file in MOL2 (Tripos Mol2) file format of each 
chemical structure from “intermediate compounds” library, MarvinView 5.5.0.1, 2011, 
ChemAxon (http://www.chemaxon.com). Based on SMILES strings for SCs and BBs and 
using a dummy linker as connector between SC and BB, SmiLib v2.0 (Schüller et al., 2003) 
generated the full virtual library (written as SMILES strings). Web-based software tool FAF-
Drugs2 (Lagorce et al., 2008), hosted on the public domain of The Ressource Parisienne en 
Bioinformatique Structurale (http://mobyle.rpbs.univ-paris-diderot.fr/cgi-bin/portal.py), was 
used to filter for “drug-likeness”, undesirable moieties and PAINS, the entire virtual library 
and BAT. As input data for FAF-Drugs2 were used SMILES strings. FAF-Drugs2 exported 
“drug-like” virtual derivates free of undesirable moieties (except of thiophene moiety) as 
compound library of “intermediate compounds” in SDF (structure data file) file format. PyRx 
– Python Prescription 0.8 (Wolf, 2009) has been used to screen “intermediate compounds” 
and BAT against the homologue model of MMP16. PyRx – Python Prescription 0.8 used 
AutoDock Vina (Trott and Olson, 2010) as docking software.  
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Building the full virtual library: SmiLib v2.0 concatenates SCs (Markush structures of 
molecules that contain sites of variability or R-groups) with BBs (small Markush molecules) 
via linkers (connectors between scaffold molecules and building blocks) using virtual 
reactions. MarvinSketch was used to draw the structures for SCs and BBs and to generate the 
input data for SmiLib v2.0 (SMILES strings for SCs and BBs). 
The thiophene moiety was conserved in the chemical structure of all twelve SCs (Fig. 
1) and was imposed one or two positions for sites of variability (R1 and R2) located in various 
positions. Eight scaffolds have only one site of variability (SC1, 3, 5, 7-10 and 12), 
meanwhile four scaffolds have two sites of variability (SC2, 4, 6 and 11). 
 
 
Fig. 1. The scaffolds based of backbone structure of BAT 
 
All BBs used to construct the virtual library are based of structural motifs most 
frequently found in some antineoplastic drugs (cyclophosphamide, mechlorethamine, 
uramustine, melphalan, carmustine, lomustine, streptozotocin, busulfan, procarbazine, 
mercaptopurine, thioguanine, methotrexate, pemetrexed and raltitrexed), which were 
previously used to improve the permeability properties of anticancer anthracyclines through 
structural modification (Tamaian et al., 2010). 
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To reduce the size and molecular weight of the virtual derivates it was used a dummy 
(empty) linker, which contains only the instructions regarding the attachment site [A] and the 
site of variability [R] and have the notation: [A][R]. 
SmiLib v2.0 constructed the full virtual library using virtual reactions and assigned the 
identifiers (IDs) for each virtual derivate using the following general definition: 
scaffold.linker1_bblock1.linker2_bblock2... 
Computational filtering to indentify the “drug-like” virtual derivates, undesirable 
moieties and PAINS has been done using exclusively with FAF-Drugs2. First, the entire 
virtual library and BAT was filtered for “drug-likeness” according to the preset specifications 
of FAF-Drugs2: 
- molecular weight (MW) between 150 Da and 600 Da; 
- number of the hydrogen bond donors (HBD) between 0 and 5; 
- number of the hydrogen bond acceptors (HBA) between 0 and 10; 
- octanol/water partition coefficient (Log P) between -4 and 5, calculated according 
XLOGP3 method developed by Cheng et al., 2007; 
- maximum one violation of the Lipinski rule of fives (vRO5) for oral bioavailability 
regarding values of MW, HBD, HBA and Log P as stated by Lipinski et al. (1997, 
2001); 
- number of the heavy atoms (HVA) between 0 and 37; 
- number of the rotatable bonds (RotB) between 0 and 15; 
- number of the rigid bonds (RB) between 0 and 30; 
- number of the chemical rings (CR) between 0 and 5; 
- maximum size of the largest ring (MxCR) = 12; 
- topological polar surface area (TPSA) between 0.00 Å and 160.00 Å, calculated 
according to the method developed by Ertl et al., 2000; 
- number of the formal charges (FC) between 0 and 3; 
- sum of the formal charges (SFC) between -2 and 2. 
In addition to those filters, it was calculated solubility (mg/l) and bioavailability was 
expressed as “good” or “bad” according both to rules of Egan et al., (2000) and Veber et al., 
(2002).  
“Drug-like” virtual derivates and BAT were checked for undesirable moieties and if 
they are PAINS. The undesirable moieties and substructures involved in toxicity issues and 
searched by FAF-Drugs2 are warheads according to Rishton (2003), frequent hitters 
according to Roche et al. (2002), promiscuous inhibitors according to McGovern et al. 
(2002), flagged or intermediate substructure according to medicinal chemistry knowledge 
(substructures or compounds that can be problematic) and other diversity moieties (excluding 
PAINS). PAINS, according to Baell and Holloway (2010), are promiscuous compounds that 
appear as frequent hitters in many biochemical high throughput screens and are increasingly 
prevalent, as promising starting points for further exploration, whereas they may not be. 
Virtual screening: prior to virtual screening and docking the individual files of each 
intermediate “drug-like” virtual derivates and BAT were 3D optimized with MarvinSketch. 
The screening software, PyRx – Python Prescription 0.8, operates with two types of 
molecules: ligands and receptors. Ligands are small molecules (test compounds) and receptors 
are macromolecules, which represent de therapeutic target of small molecules.  
As receptor it was used a homologue model of MM16 for Homo sapiens 
(UniProtKB/Swiss-Prot ID: P51512) built-up on the base of the crystal structure of the 
catalytic domain of MMP16 (PDB ID: 1rm8) using the public domain of SWISS-MODEL 
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Repository (http://swissmodel.expasy.org/repository/), (Kiefer et al., 2009; Kopp and 
Schwede, 2004).  
PyRx – Python Prescription 0.8 use AutoDock Vina as docking software and 
AutoDock Vina in order de operate requires structures of the molecules being docked and 
grid-boxes to define the binding site (search space). AutoDock Vina do not need to calculate 
the grid maps and to assign atom charges. The predicted binding affinity of bound structures 
is given in kcal/mol. To compare the accuracy of the predictions of the experimental structure, 
AutoDock Vina use a measure of distance between the experimental and predicted structures 
– RMSD (root-mean-square deviation). RMSD metrics are expressed as RMSD lower bound 
(rmsd/lb) and RMSD upper bound (rmsd/ub), differing in how the atoms are matched in the 
distance calculation. For scoring, AutoDock Vina uses a united-atom function, which involves 
only the heavy atoms. 
To start virtual screening, all ligands and the receptor were loaded in PyRx – Python 
Prescription 0.8 graphic user interface (GUI) and search space was set as following:  
- center coordinates: X = 9.5101; Y = 12.0527; Z = 46.1456; 
- dimensions (Å): X = 25.0000; Y = 25.0000; Z = 25.0000. 
After Autodock Vina calculated de lowest binding affinities and RMSD metrics, 
docking results were displayed and analyzed in the GUI of PyRx – Python Prescription 0.8.  
 
RESULTS AND DISCUSSIONS 
 
Using virtual reactions, SmiLib v2.0 concatenated the twelve SCs (eight with one site 
of variability and four of them with two sites of variability) and forty BBs using a dummy 
linker as connector between them. The full virtual library contains 6720 virtual derivates 
displayed as SMILES strings (Fig. 2). 
 
 
Fig. 2. GUI of SmiLib v2.0 with enumeration of virtual library (6720 virtual derivates) 
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Each of the eight SCs with one site of variability (SC1, 3, 5, 7-10 and 12) generated 40 
virtual derivates with 40 BBs (1x40=40). Each of the scaffolds with two sites of variability 
(SC2, 4, 6 and 11) generated 1600 virtual derivates with 40 BBs (1x40x40=1600). The 
resulted virtual library contains 320 (5%) compounds from SCs with one site of variability 
and 6400 (95%) compounds from SCs with two sites of variability.  
Computational filtering done with FAF-Drugs2 qualified as “drug-like” virtual 
derivates only 86 (1%) compounds, meanwhile 6634 (99%) compounds were rejected (data 
not shown).  
Filtering the “drug-like” virtual derivates for undesirable moieties revealed that 62 
compounds were rejected due to severe risk to heath caused especially by warhead moieties. 
The rest of 24 virtual derivates are considered intermediate compounds due their thiophene 
moiety (data not shown). 
Filtering the “drug-like” virtual derivates for PAINS reveal that only 5.1_16 can be a 
such as promiscuous compound (data not shown) and cannot be considered an intermediate 
compound .  
 
Tab. 1. 



















































BAT 477.64 4 7 3.55 0 32 12 17 2 6 161.07 0 0 6083.19 
5.1_2 466.55 2 6 2.93 0 30 10 21 3 6 147.85 0 0 8141.83 
5.1_3 481.57 3 7 2.66 0 31 10 22 3 6 159.88 0 0 9116.63 
5.1_4 495.60 3 7 2.25 0 32 11 21 3 6 159.88 0 0 11967.74 
5.1_12 457.57 2 7 2.82 0 31 9 23 3 6 154.57 0 0 7745.82 
7.1_2 424.52 2 5 2.81 0 27 9 20 3 6 130.78 0 0 9586.33 
7.1_3 439.53 3 6 3.13 0 28 10 20 3 6 142.81 0 0 7938.12 
7.1_4 453.56 3 6 2.67 0 29 10 20 3 6 142.81 0 0 10106.08 
7.1_11 415.53 3 6 2.51 0 28 9 21 3 6 148.36 0 0 10851.90 
7.1_12 415.53 2 6 2.70 0 28 9 21 3 6 137.50 0 0 9627.66 
7.1_13 415.53 3 6 2.51 0 28 9 21 3 6 148.36 0 0 10851.90 
7.1_20 392.50 3 7 2.90 0 26 9 17 2 6 158.40 0 0 10026.01 
7.1_21 392.50 3 7 3.12 0 26 10 17 2 6 153.20 0 0 9323.92 
7.1_29 455.62 1 6 4.16 0 30 9 24 3 9 159.21 0 0 3614.38 
7.1_35 539.71 3 7 5.00 1 37 14 22 3 6 152.28 1 -1 2033.36 
7.1_36 539.71 3 7 5.00 1 37 14 22 3 6 152.28 1 -1 2033.36 
7.1_38 506.68 2 6 4.02 1 35 11 25 3 10 131.63 1 1 3360.74 
8.1_2 480.58 1 6 3.11 0 31 10 21 3 6 139.06 0 0 6908.57 
8.1_3 495.60 2 7 2.84 0 32 10 22 3 6 151.09 0 0 7725.41 
8.1_4 509.62 2 7 2.43 1 33 11 21 3 6 151.09 0 0 10127.64 
8.1_11 471.59 2 7 2.93 0 32 10 22 3 6 156.64 0 0 7378.89 
8.1_12 471.59 1 7 3.00 0 32 9 23 3 6 145.78 0 0 6609.60 
8.1_13 471.59 2 7 2.93 0 32 10 22 3 6 156.64 0 0 7378.89 
10.1_2 487.57 4 6 3.50 0 32 8 26 4 6 156.80 0 0 4243.31 
Note: Underlined values represent violations of RO5 according with the specifications of the authors 
(Lipinski et al., 1997, 2001) for a good bioavailability: MW ≤ 500 Da, HBD ≤ 5, HBA ≤ 10 and CLog P ≤ 5. 
Violation of a single rule does not disqualify a compound for being bioavailable.  
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In Tab. 1 are summarized the results of FAF-Drugs filtering for “drug-like” 
compounds, selectively presented only for BAT and “drug-like” virtual derivates free of for 
undesirable moieties and definitely not PAINS.  
Based on result from Tab. 1, FAF-Drugs qualified BAT and all “drug-like” virtual 
derivates free of for undesirable moieties and definitely not PAINS as having a “good” 
bioavailability according both to rules of Egan et al., (2000) and Veber et al., (2002). 
However, BAT presents a value of TPSA higher than the upper limit, which can affects the 
human intestinal absorption, Caco-2 monolayer permeability, and blood-brain barrier 
penetration of this compound. The 23 “drug-like” virtual derivates free of for undesirable 
moieties and definitely not PAINS qualified as intermediate compounds don not overpass the 
TPSA value. 
Analyzing the origin of intermediate compounds from Tab. 1 it can be observed that 
not even a single virtual derivate based on any of SCs with two sites of variability has been 
qualified as intermediate compound according the imposed criteria, even those derivates 
represents 95% of entire virtual library.  
The virtual screening results show that all intermediate compounds are strong 
inhibitors of MMP16 (Tab. 2). 
Tab. 2 
Docking results (only the lowest energy for each compound corresponding  to the best bound 
structure prediction are showed)  







MM16 - 7.1_38 -9.50 0.00 0.00 
MM16 - 10.1_2 -9.10 0.00 0.00 
MM16 - 8.1_13 -9.00 0.00 0.00 
MM16 - 5.1_12 -8.90 0.00 0.00 
MM16 - 7.1_13 -8.90 0.00 0.00 
MM16 - 5.1_4 -8.80 0.00 0.00 
MM16 - 7.1_21 -8.80 0.00 0.00 
MM16 - 7.1_12 -8.70 0.00 0.00 
MM16 - 8.1_3 -8.70 0.00 0.00 
MM16 - 8.1_11 -8.70 0.00 0.00 
MM16 - 7.1_11 -8.60 0.00 0.00 
MM16 - 7.1_20 -8.60 0.00 0.00 
MM16 - 7.1_29 -8.60 0.00 0.00 
MM16 - 7.1_36 -8.60 0.00 0.00 
MM16 - 7.1_4 -8.50 0.00 0.00 
MM16 - 7.1_35 -8.50 0.00 0.00 
MMP16 - BAT -8.40 0.00 0.00 
MMP16 - 5.1_3 -8.30 0.00 0.00 
MMP16 - 7.1_2 -8.30 0.00 0.00 
MMP16 - 5.1_2 -8.20 0.00 0.00 
MMP16 - 8.1_4 -8.20 0.00 0.00 
MMP16 - 7.1_3 -8.10 0.00 0.00 
MMP16 - 8.1_2 -7.70 0.00 0.00 
MMP16 - 8.1_12 -7.70 0.00 0.00 
Note: Results are showed arranged from the strongest ligand (top) to the weaker ligand (bottom). 
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The RMSD cutoff of 2Å is usually used as criteria of the correct bound structure 
prediction (Bursulaya et al., 2003). Using the same cutoff value, the two metrics used for 
RMSD (summarized in Tab. 2) indicate that all predictions for tested compounds are very 
accurate. Results from Tab. 2 indicate that 15 intermediate compounds are better ligands of 
MMP16 than BAT because they require a lesser energy for biding; one compound presents 
the same binding affinity as BAT and 7 intermediate compounds are weaker ligands than 
BAT.  
From the Fig. 3 it can be observed that all tested compounds bind in the active site of 
MMP16, having various spatial orientations correlated with their spatial conformation.  
 
 




In this work, a computational approach was used to identify safer and better inhibitors 
of MMPs aimed to reduce the amplification of the proliferative response to growth factors, 
promotion of cancer cell invasion and tumoral growth. Using a large virtual library based on 
backbone structure of BAT, a severe selection of the safer “drug-like” virtual derivatives has 
been made using mass-computation methods. The virtual screening and molecular docking 
revealed 16 “drug-like” virtual derivatives, which are not only safer than BAT, but they are 
also much stronger ligands. Computational techniques represent a preliminary work in drug 
development process, which help to prioritize the organic syntheses and biochemical 
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